Gut bugs brew trouble Leading edge Toronto Ottawa Heart Summit adds primary care perspective to June agenda Should CPR guidelines be different in rural areas? Review uncovers deficiencies in patient information on warfarin Assessment finds patient education sheets lack some important content needed for safe use of this drug. Beware high heart rate Draw declared in off- versus on-pump CABG trial Results show no differences in one-year outcomes Clot-blocking implant improves safety Device intended as alternative to oral anticoagulants in atrial fibrillation Bust that clot! STEMI trial touts benefits of pre-hospital fibrinolysis Edarbi and Edarbyclor for hypertension Takeda Canada is introducing a new angiotensin II blocker (ARB) for the treatment of hypertension. Bystolic: new beta-blocker for hypertension Forest Laboratories will soon launch a new once-daily beta-blocker for the treatment of mild to moderate essential hypertension. First Previous 52 53 54 55 56 Next Last
